Equities research analysts forecast that Bristol-Myers Squibb (NYSE:BMY) will report sales of $11.31 billion for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Bristol-Myers Squibb’s earnings, with estimates ranging from $10.78 billion to $11.64 billion. Bristol-Myers Squibb posted sales of $10.13 billion during the same quarter last year, which suggests a positive year over year growth rate of 11.6%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 5th.
On average, analysts expect that Bristol-Myers Squibb will report full year sales of $46.00 billion for the current fiscal year, with estimates ranging from $45.21 billion to $46.51 billion. For the next fiscal year, analysts forecast that the firm will report sales of $47.75 billion, with estimates ranging from $47.05 billion to $48.53 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Wednesday, April 28th. The biopharmaceutical company reported $1.74 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.82 by ($0.08). Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The company had revenue of $11.07 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same period in the previous year, the business posted $1.72 earnings per share. The firm’s revenue was up 2.7% compared to the same quarter last year.
BMY has been the subject of a number of research analyst reports. TheStreet raised Bristol-Myers Squibb from a “c” rating to a “b” rating in a report on Thursday, April 29th. Truist Financial raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, April 13th. Truist raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, April 13th. Truist Securities upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $66.00 to $74.00 in a research report on Monday, April 19th. Finally, Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research report on Tuesday, April 6th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $73.81.
Shares of Bristol-Myers Squibb stock traded up $0.47 during trading on Thursday, reaching $63.95. The company’s stock had a trading volume of 10,559,876 shares, compared to its average volume of 12,425,299. The stock has a 50-day moving average price of $63.60 and a two-hundred day moving average price of $63.04. The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82. Bristol-Myers Squibb has a one year low of $54.07 and a one year high of $67.16. The stock has a market capitalization of $142.79 billion, a P/E ratio of -577.04, a price-to-earnings-growth ratio of 1.00 and a beta of 0.67.
The business also recently announced a quarterly dividend, which was paid on Monday, May 3rd. Stockholders of record on Thursday, April 1st were given a dividend of $0.49 per share. The ex-dividend date of this dividend was Wednesday, March 31st. This represents a $1.96 annualized dividend and a dividend yield of 3.06%. Bristol-Myers Squibb’s payout ratio is currently 41.79%.
In other news, CEO Giovanni Caforio sold 25,000 shares of the business’s stock in a transaction dated Monday, March 22nd. The stock was sold at an average price of $62.20, for a total transaction of $1,555,000.00. Following the completion of the transaction, the chief executive officer now directly owns 528,980 shares in the company, valued at approximately $32,902,556. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.14% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Retirement Group LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $27,000. Orion Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $28,000. Perennial Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $29,000. Brand Asset Management Group Inc. acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at approximately $31,000. Finally, Founders Capital Management acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 72.41% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
See Also: Non-Fungible Token (NFT) Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.